Piedmont Oncology Launches Enhanced Program for Pancreatic Cancer Detection and Treatment Initiatives
- Piedmont Oncology's donation enhances its Early Detection Pancreatic Cancer Clinic, now named the Sherron Berg Early Detection Pancreatic Cancer Program.
- The clinic, established in 2025, focuses on risk assessments and early detection to improve pancreatic cancer patient outcomes.
- Philanthropy is vital for Piedmont Oncology’s mission to advance innovative treatments and research in pancreatic cancer care.
Piedmont Oncology Takes Significant Steps in Pancreatic Cancer Detection and Treatment
Piedmont Oncology is poised to strengthen its commitment to battling pancreatic cancer through a major philanthropic donation aimed at enhancing its Early Detection Pancreatic Cancer Clinic (EDC). This substantial investment not only boosts clinical operations and research initiatives but also facilitates a rebranding of the clinic, which will now be known as the Sherron Berg Early Detection Pancreatic Cancer Program. The donation will also allow for the establishment of an endowed medical director position, a post now filled by the clinic's founder, Dr. Andrew Page. Dr. Page expresses enthusiasm about the transformative power of this gift, highlighting the necessity for continued philanthropic support in combatting this aggressive form of cancer.
The clinic, recognized as the first of its kind in Georgia, originally opened its doors in November 2025 at Piedmont Atlanta Hospital. It offers comprehensive risk assessments, improved awareness, and accessible services for both patients and clinicians. The clinic focuses on early detection, a crucial factor in improving outcomes for pancreatic cancer patients, which is notorious for its high mortality rate. Currently, pancreatic cancer ranks as the fourth leading cause of cancer-related deaths in the United States, with only a grim five-year survival rate of 13%, according to the American Cancer Society. This donation and the resulting enhancements at the EDC align with Piedmont Oncology’s mission to promote innovative treatments and facilitate earlier diagnoses.
The honoree of this significant investment, Sherron Berg, knows firsthand the importance of early detection, having been diagnosed with Stage 2 pancreatic cancer in 2023. Her experience with a Whipple surgery performed by Dr. Page has notably increased her chances of survival. The Berg family's vision is consistent with the clinic’s objectives by driving forward initiatives that prioritize early detection and effective treatment solutions for pancreatic cancer. Contributions to support the Sherron Berg Early Detection Pancreatic Cancer Program can be made through their dedicated website, with patients able to enter the clinic either by referral or via self-referrals.
As Piedmont Oncology embarks on this transformative journey, it remains clear that philanthropy plays a critical role in advancing cancer care, particularly in the realm of pancreatic cancer, where early detection can significantly change prognosis. The integration of new initiatives and dedication to research will further consolidate the clinic’s reputation as a leader in the fight against this formidable disease.